中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
2-溴-6-甲氧基苯酚 | 6-bromoguaiacol | 28165-49-3 | C7H7BrO2 | 203.035 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
1,2,3-三溴-4,5-二甲氧基苯 | 2,3,4-tribromoveratrole | 854872-30-3 | C8H7Br3O2 | 374.854 |
—— | 3,4,5-tribromo-2-(2',4'-dibromophenoxy)anisole | 38926-88-4 | C13H7Br5O2 | 594.717 |
To report a case of changes documented by magnetic resonance imaging (MRI) of the head probably due to accumulation of metronidazole in a patient with liver dysfunction.
A 34-year-old Hispanic man with cirrhosis and hepatitis C being treated with metronidazole for Bacteroides fragilis meningitis and bacteremia developed ataxia, disorientation, and peripheral neuropathy. An MRI at the time meningitis was diagnosed was negative. After the patient received >60 g of metronidazole, an MRI revealed increased signal intensity below, behind, and lateral to the fourth ventricle. Concomitant metronidazole serum concentration was toxic at 35.1 μg/mL.
This is the second reported case of metronidazole-induced MRI changes. Metronidazole is known to accumulate in patients with liver dysfunction and can cause peripheral neuropathy and central nervous system (CNS) dysfunction; these effects may take up to two years to completely resolve.
Metronidazole dosages should be reduced in patients with liver dysfunction to prevent the accumulation of metronidazole, which can lead to CNS dysfunction and peripheral neuropathy.
报告一例头部磁共振成像(MRI)显示的变化,可能是由于肝功能障碍患者体内甲硝唑积累所致。
一名34岁的西班牙裔男子患有肝硬化和丙型肝炎,因拜杆菌脑膜炎和菌血症接受甲硝唑治疗,出现共济失调、定向障碍和周围神经病变。脑膜炎确诊时进行的MRI检查结果为阴性。患者接受了超过60克的甲硝唑后,MRI显示第四脑室下方、后方和侧面信号强度增加。同时,甲硝唑血清浓度达到35.1μg/mL,毒性较大。
这是第二例报告的甲硝唑诱导的MRI变化。甲硝唑已知会在肝功能障碍患者体内积累,并可导致周围神经病变和中枢神经系统(CNS)功能障碍;这些影响可能需要长达两年的时间才能完全消除。
应该在肝功能障碍患者中减少甲硝唑剂量,以防止甲硝唑积累,从而导致CNS功能障碍和周围神经病变。